ArticlePharmacoEconomics2024

Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective.

Giovany Orozco-Leal et al.PubMed ↗Publisher ↗

No numbers read from the abstract.